Retatrutide 5 mg – 10 Vials

Retatrutide is a novel triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, representing the next generation of metabolic therapeutics. Currently in Phase 3 clinical trials, retatrutide has demonstrated unprecedented weight loss results, with participants losing an average of 24-28% of body weight in 48-week Phase 2 trials. This triple mechanism combines appetite suppression and glucose control (GLP-1), enhanced insulin secretion and metabolic effects (GIP), and increased energy expenditure with preserved lean mass (glucagon). Unlike selective GLP-1 or dual GLP-1/GIP agonists, the addition of glucagon receptor activation promotes fat oxidation, increases metabolic rate, and helps prevent the muscle loss typically associated with significant weight reduction. Retatrutide is administered once weekly via subcutaneous injection and has shown a favorable safety profile in trials to date